Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > It's on Twitter... ASCO Results

<< Previous

Bullboard Posts

Next >>

Comment by Noteableon Jun 04, 2023 6:26pm

197 Views

Post# 35479477

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:It's on Twitter... ASCO Results

The earlier October 2022 cut-off PFS results involving pelareorep as a single agent are being sustained 7 months later - well into the May 2023 cut-off date - which is a "Good Thing", and demonstrates that the single agent pelareorep (+ paclitaxel) treatment is not only effective but enduring when compared to the standard of care (SOC) control group (paciltaxel alone).

https://www.oncolyticsbiotech.com/press-releases/press-releases/detail/599/oncolytics-biotech-announces-positive-randomized-phase-2

<< Previous

Bullboard Posts

Next >>

From now on, dynaCERT instead of Bitcoin or NVIDIA?